What Mixtard 30 FlexPen Treats: Main Uses and Benefits

The primary role of Mixtard 30 FlexPen is commonly used to help with managing blood sugar levels for patients requiring external insulin, addressing the core metabolic issue of hyperglycemia in various clinical contexts. The preparation is applied in the treatment of diabetes mellitus.

---

Core Therapeutic Scope

This medication is applied across domains where supportive insulin replacement therapy is appropriate for the chronic management of Diabetes Mellitus, including Type 1 diabetes and Type 2 diabetes when oral treatments may be insufficient. It is relevant for managing symptoms that interfere with daily comfort, such as persistent high blood glucose and the rapid spikes that follow meals. The dual action supports integrated management, assisting the patient in supporting stability across the daily cycle and contributes to improved comfort during symptomatic periods.

“The preparation’s biphasic composition is considered relevant for patients needing a balance between immediate glucose correction and prolonged background maintenance.”

Quick Fact: Relief for Blood Glucose Fluctuations Mixtard 30 FlexPen is commonly used to help with addressing two crucial daily symptomatic needs: the acute glucose spikes that occur immediately after meals and the requirement for stable background (basal) glucose between meals and overnight. The key therapeutic benefit supports general well-being and metabolic stability. This biphasic insulin formulation is commonly used as a therapeutic tool for adults, adolescents, and children with diabetes who require this combined approach.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Mixtard 30 FlexPen eligibility is governed by official regulatory criteria that specify both approved populations and absolute prohibitions.

Who Cannot Use Mixtard 30 FlexPen

Use is contraindicated for patients with a known hypersensitivity (allergy) to the active substance, Insulin human, or to any of the product's excipients. Furthermore, the medicine must not be injected during an episode of hypoglycaemia (low blood sugar) or if the condition is suspected.

Age and General Eligibility Status

The medicine is approved for use in adults, adolescents, and children. Eligibility is also established for elderly patients aged 65 years and older. For women who are pregnant or breastfeeding, treatment can be maintained, although intensified glucose monitoring is necessary during pregnancy.

Populations Requiring Conditional Use

Official labeling defines groups for whom use is permitted but requires intensified glucose monitoring and individual dose adjustment. This includes patients with renal impairment, hepatic impairment, or concomitant diseases affecting the adrenal, pituitary, or thyroid gland. Use in combination with pioglitazone is restricted for patients with risk factors for cardiac heart failure.

Interactions with other medicines and products

This section summarizes interactions with Mixtard 30 FlexPen as documented in official government regulatory information. Most documented interactions are pharmacodynamic, meaning they influence the patient's glucose metabolism and affect the required insulin level.

---

Substances Documented to Affect Insulin Requirement

Interaction Type	Examples of Documented Interacting Substances
May Reduce Insulin Requirement (Potentiate Effect)	Oral antidiabetic products, Monoamine oxidase inhibitors (MAOI), Angiotensin-converting enzyme (ACE) inhibitors, Salicylates, Anabolic steroids.
May Increase Insulin Requirement (Antagonize Effect)	Oral contraceptives, Glucocorticoids, Thiazides, Thyroid hormones, Sympathomimetics, Growth hormone.
Variable Effect	Octreotide/Lanreotide, Alcohol, Beta-blockers.

---

Specific Interaction Risks and Constraints

• Organ Risk: Co-administration with Pioglitazone (a thiazolidinedione) is documented with reports of cardiac failure, especially in patients with pre-existing risk factors.
• Symptom Masking: Beta-blockers are specifically noted in regulatory labels as potentially masking the typical warning signs of hypoglycemia.
• Alcohol: Consumption of alcohol may unpredictably either intensify and prolong or reduce the blood-glucose-lowering effect.
• Administration Restriction: Mixtard 30 FlexPen must not be mixed with any other insulin product in the administration device.
• Condition-Specific Note: Renal impairment and hepatic impairment are conditions documented to potentially reduce the patient’s insulin requirements.

Mixtard 30 FlexPen contains human insulin, which exerts its effect by binding to the Insulin Receptor (IR), a cell-surface tyrosine kinase receptor located on key metabolic cells including adipocytes, hepatocytes, and myocytes. This binding activates the intracellular receptor domain, initiating a tyrosine kinase signaling cascade involving Insulin Receptor Substrates (IRS) proteins.

This cascade primarily activates the PI3K/Akt pathway, leading to the translocation of Glucose Transporter 4 (GLUT4) vesicles to the plasma membrane of muscle and fat cells. This process facilitates the uptake of circulating glucose into peripheral tissues. Concurrently, in the liver, the mechanism causes a reduction in hepatic glucose output by inhibiting the metabolic processes of gluconeogenesis and glycogenolysis. The overall effect is a coordinated anabolic action that leads to a reduction in plasma glucose concentration.

The formulation contains a blend of soluble (rapid-acting) and isophane (intermediate-acting) insulin. This biphasic profile results in a dual pharmacodynamic action: the rapid component facilitates immediate glucose clearance following nutrient intake, while the intermediate component provides sustained receptor binding and pathway activity to inhibit hepatic glucose production over a longer duration.

Administration and Handling

Mixtard 30 FlexPen is a pre-filled, multidose pen containing a biphasic insulin suspension. Proper handling is necessary to ensure the insulin is mixed correctly and the device functions as intended.

Preparation of the Suspension

Before using the pen for the first time, or if the pen has not been used for a period, the insulin suspension must be resuspended. This process involves bringing the insulin to room temperature and gently moving the pen to ensure the liquid becomes uniformly white and cloudy. This is typically achieved through a series of designated movements, such as rolling the pen between the palms or rotating it up and down.

Needle Attachment and Priming

The device is designed to be used with compatible disposable needles. A new needle should be used for every administration. Before the insulin is delivered, it is necessary to perform a function check, often referred to as priming, to remove air bubbles and ensure that the needle is not blocked. This process involves selecting a small number of units and dispensing them into the air until a drop of insulin appears at the needle tip.

Injection Technique

The insulin is administered via subcutaneous injection. Common injection sites include the abdominal wall, the thighs, the buttocks, or the upper arms. To help prevent skin changes at the injection site, such as thickening or pitting, the specific site of injection should be rotated within the chosen anatomical region.

After the needle is inserted into the skin, the dose button is pressed fully. Following the delivery of the dose, the needle should remain under the skin for a brief period to ensure that the full amount of insulin has been administered.

Storage and Care

The pen should be stored without the needle attached to prevent leakage, contamination, and the entry of air. The cap should be replaced on the pen after use to protect the insulin from light. The device is intended for individual use only and should not be shared.

Research evidence / Overview of Studies for Mixtard 30 FlexPen

Evidence for Use in Diabetes Mellitus

Studies were conducted for the use of this biphasic human insulin in individuals diagnosed with Diabetes Mellitus, covering both Type 1 and Type 2 diabetes. Research relied primarily on Randomized Controlled Trials (RCTs) and various observational studies. The main goal of these studies was to understand how the medicine was observed in addressing blood sugar levels or physiological strain or stress related to glucose.

The core research tracked the long-term biomarker: Glycosylated Hemoglobin ( HbA1c). This measurement reflects blood sugar patterns over a period of several months. Studies reported measurements of changes in HbA1c levels, reflecting how blood sugar patterns evolved in the observed populations. Research also examined the acute outcomes related to functional imbalance, specifically blood sugar changes that happen after meals.

---

Study Focus: Short-Term Blood Glucose Control

Studies were conducted to examine the preparation’s mix of fast-acting and intermediate-acting insulin, which was studied for its association with daily blood sugar profiles. Specialized Pharmacodynamic (PD) studies were evaluated to describe the timing of the peak insulin effect and the total duration of its activity.

Studies focusing on outcomes describing episodic or acute changes (such as acute glucose spikes) examined how the two insulin components data show patterns related to blood sugar concentrations measured shortly after a meal. This evidence was evaluated in research exploring short-term symptom changes over defined time intervals, often 24-hour periods.

---

Long-Term Research and Durability of Effect

The majority of efficacy data used for regulatory review comes from short-term periods, typically with follow-up durations of about 12 weeks (three months) to allow for the measurement of HbA1c changes. However, long-term outcomes are not fully established through extensive prospective trials extending over several years. Large-scale research focusing specifically on long-term measured outcomes or observation periods far beyond the initial study period remains limited.

---

Evidence in Special Study Populations

Studies also explored the use of this biphasic insulin preparation in children and adolescents, a specific age group where the medicine was evaluated in the context of youth-onset diabetes. For other specific groups, such as older adults and individuals with kidney or liver impairment, the available data for certain groups remain insufficient. Regulatory information notes that the medicine was observed in these populations, but limited information for long-term outcomes means the results apply only to the populations studied in the primary trials.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index - Insulin human

Common questions about Mixtard 30 FlexPen (FAQ)

---

Q: How quickly does the rapid-acting component of Mixtard 30 typically begin to work?

Official product information indicates that the fast-acting component of Mixtard 30 typically begins to lower blood sugar around 30 minutes after injection. This rapid component is described as facilitating immediate glucose clearance following nutrient intake.

---

Q: What is the expected total duration of action of one dose of Mixtard 30?

According to regulatory sources, the dual components of Mixtard 30 are formulated to provide a total duration of action that may last for approximately 24 hours after a single dose. This biphasic profile is observed to provide action for both immediate post-meal needs and sustained metabolic control.

---

Q: What are the general signs of a rare, severe allergic reaction to Mixtard 30?

Official documents list rare, systemic hypersensitivity (anaphylaxis) as a possible adverse reaction. The general signs of such a reaction, as documented in regulatory sources, include a widespread skin rash, itching, sweating, swelling of the face or throat, breathing difficulties, palpitations, and a sudden reduction in blood pressure.

---

Q: Is Mixtard 30 FlexPen a newer or older type of diabetes treatment?

Mixtard 30 contains human insulin, which is considered a long-established, classical type of insulin. Regulatory records show the product has been in clinical use for many years, with approvals dating back to at least 1995.

---

Q: What are some common misunderstandings about the correct operation of a FlexPen device?

Official administration guidelines emphasize crucial steps that users sometimes overlook. For example, the pen should be resuspended immediately before use until it looks uniformly white and cloudy. Also, the needle is generally instructed to be kept under the skin for at least 6 seconds after fully pressing the dose button to ensure that the medication is delivered.

---

Q: What is the typical appearance of Mixtard 30 before it is thoroughly mixed?

Mixtard 30 is a suspension that will separate over time. Before use, the pen must be rolled and inverted until it is uniformly white and cloudy. Official guidance indicates that the medicine should not be used if it appears clear or contains clumps or solid particles.

---

Q: Does Mixtard 30 interact with common over-the-counter pain relievers like ibuprofen?

Regulatory information lists Salicylates (a class of pain relievers) as substances that may reduce insulin requirements. Although other non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are not specifically listed, the influence of any over-the-counter pain reliever on blood glucose control is a factor for healthcare consideration.

---

Q: Why is the injection device called a 'FlexPen'?

The name 'FlexPen' refers to a specific brand of pre-filled, multi-dose insulin pen device developed by the manufacturer. This device is designed for convenience, allowing the user to dial and deliver doses in 1-unit increments up to 60 units.

---

Q: How is the Mixtard 30 FlexPen generally stored before and after first use?

According to official product information, the Mixtard 30 FlexPen should be stored in a refrigerator (2°C to 8°C) before it is opened. Once the pen is in use, it should be stored for a maximum of 6 weeks at a temperature below 30°C.

---

Q: What happens if the medicine is accidentally exposed to freezing temperatures?

Official guidance indicates that the insulin should never be frozen. If the medicine is accidentally exposed to freezing temperatures, it should be discarded, as freezing can lead to chemical degradation and a loss of the product’s intended potency.

---

Q: Is Mixtard 30 FlexPen available in different dose concentrations or formats?

Mixtard is generally supplied at a standard concentration of 100 International Units per milliliter (IU/mL). Official product information confirms that it is available in several formats, including the FlexPen (pre-filled pen), Penfill (cartridge), and a standard vial formulation.

---

Q: Is the use of Mixtard 30 commonly prescribed or studied during pregnancy?

The use of human insulin during pregnancy is generally acknowledged in regulatory contexts. Maintaining good metabolic control is noted as being vital throughout pregnancy, and insulin requirements typically increase during the second and third trimesters.

---

Q: What is the primary difference between Mixtard 30 and Mixtard 50?

The key difference is the ratio of fast-acting to intermediate-acting human insulin. Mixtard 30 contains 30% fast-acting insulin, whereas Mixtard 50 contains 50% fast-acting insulin. This distinction results in a different insulin action profile.

---

Q: Can people who are making major changes to their diet or exercise routine use Mixtard 30?

Official documents state that significant lifestyle changes, such as major adjustments to diet or exercise, can alter glucose metabolism. This means that the patient's insulin requirements may be altered, a situation which may require dosage adjustment by a healthcare professional.

---

Q: Does traveling across different time zones impact the general management of Mixtard 30 use?

Traveling across different time zones can significantly disrupt the timing of meals and insulin injections. Regulatory contexts suggest consulting a healthcare team to create an adjusted schedule to manage blood glucose control during travel.

---

Q: What is the difference between Novolin 70/30 and Mixtard 30?

Mixtard 30 and Novolin 70/30 are both premixed insulins containing Human Insulin components. The primary difference is the ratio: Mixtard 30 has 30% fast-acting, while Novolin 70/30 contains 70% intermediate-acting to 30% regular (fast-acting) insulin.

---

Q: Is there a maximum number of days a Mixtard 30 FlexPen can be used once opened?

According to the official storage instructions, once the Mixtard 30 FlexPen has been opened and is in use, it can be stored for a maximum of 6 weeks (42 days). It should be kept below 30°C during this time.

---

Q: Can other medicines used for weight loss interact with Mixtard 30?

Regulatory information and clinical practice acknowledge that medications used for weight loss may affect glucose metabolism. If such medicines are co-administered, a modification of Mixtard 30 dosage may be a factor for professional consideration to manage the patient's blood sugar levels.

How to Store and Dispose of Mixtard 30 FlexPen

Official regulatory guidelines establish specific storage conditions to maintain product stability and proper disposal procedures for safety.

Condition	Requirement
Unopened Storage	Must be kept refrigerated between 2 C and 8 C.
In-Use Storage	Store at room temperature (typically below 30 C) and do not refrigerate.
Protection	Keep in the original carton to protect from light. Do not freeze (discard if frozen).
Stability	An opened pen must be discarded after 28 days, even if some medicine remains.
Child Safety	Keep the pen and all supplies out of the reach and sight of children.
Disposal	Used needles must be placed immediately into an approved sharps container. Expired or unused pens should be disposed of according to local pharmaceutical waste regulations, not in household trash.